Jeffrey C Goh
机构: University of Queensland, Royal Brisbane & Women's Hospital
每年引用次数
引用次数
引用: 7,602
H-指数: 29
I10-指数 : 56
出版物: 178
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety
Ana Oaknin , Amit M Oza , Domenica Lorusso , Carol Aghajanian
Cancer medicine 10 ( 20) 7162 -7173
6
2021
Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: results from the phase III study ARIEL3
DAVID M O'Malley , Amit M Oza , Domenica Lorusso , Carol Aghajanian
Gynecologic Oncology 159 74 -75
3
2020
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).
Tanya Kwan , Amit M Oza , Domenica Lorusso , Carol Aghajanian
Journal of Clinical Oncology 39 ( 15_suppl) 5537 -5537
1
2021
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
J Weberpals , A Oza , Domenica Lorusso , G Scambia
International Journal of Gynecologic Cancer 30 ( Suppl 3)
1
2020
Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.
Robert L Coleman , Amit M Oza , Domenica Lorusso , Carol Aghajanian
Journal of Clinical Oncology 40 ( 16_suppl) 5544 -5544
2022
The Effect of Age on Efficacy and Safety Outcomes with Rucaparib: A Post Hoc Exploratory Analysis of ARIEL3, a Phase 3, Randomized, Placebo-Controlled Maintenance Study in Patients with Recurrent Ovarian Carcinoma
Jonathan A Ledermann , Amit M Oza , Domenica Lorusso , Carol Aghajanian
ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
Jeffrey C Goh , Sally Baron-Hay , Tony Bonaventura , Martin Buck
Asia-Pacific Journal of Clinical Oncology 14 196 -196
1
2018
Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.
Natalie YL Ngoi , Haoyang Sun , Chel Hun Choi , Valerie Heong
Journal of Clinical Oncology 41 ( 16_suppl) e17564 -e17564
2023
Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial.
Katrin Marie Sjoquist , Alexander Dobrovic , Kristy Robledo , Sally E Baron-Hay
Journal of Clinical Oncology 41 ( 16_suppl) e15079 -e15079
1
2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer , Paul Russo , Viktor Grünwald , Yoshihiko Tomita
The Lancet 401 ( 10379) 821 -832
75
2023
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
Robert J Motzer , Paul Russo , Viktor Grünwald , Yoshihiko Tomita
Journal of Clinical Oncology 41 ( 16_suppl) 4506 -4506
6
2023
Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
Robert J Motzer , Axel Bex , Paul Russo , Yoshihiko Tomita
Journal of Clinical Oncology 42 ( 4_suppl) LBA358 -LBA358
1
2024
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer , Paul Russo , Viktor Grünwald , Yoshihiko Tomita
Targeted Oncology 18 ( 5) 639 -641
2023
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Jeffrey C Goh , Jermaine Coward , Bo Gao , Ines Pires da Silva
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 17 65 -65
1
2021
Effect of novel autologous immune training platform on end-stage patients with cancer.
John F Pulford , James A Lederer , E Murzin , D Younger
Journal of Clinical Oncology 42 ( 16_suppl) 2546 -2546
2024
A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).
David Shao Peng Tan , Chel Hun Choi , Natalie Ngoi , Haoyang Sun
Journal of Clinical Oncology 40 ( 16_suppl) 5565 -5565
11
2022
Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial.
Viktor Grünwald , Robert J Motzer , John BAG Haanen , Manuela Schmidinger
Journal of Clinical Oncology 42 ( 4_suppl) 364 -364
1
2024
Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial
Emmanuel S Antonarakis , Se Hoon Park , Jeffrey C Goh , Sang Joon Shin
Journal of Clinical Oncology 41 ( 22) 3839 -3850
32
2023
Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
Niven Mehra , Emmanuel S Antonarakis , Se Hoon Park , Jeffrey C Goh
Journal of Clinical Oncology 41 ( 6_suppl) 131 -131
2
2023
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).
Evan Y Yu , Se Hoon Park , Jeffrey C Goh , Sang Joon Shin
Journal of Clinical Oncology 42 ( 16_suppl) 5064 -5064
2024